Historical Search
Clear historical searches
Common Searches
试剂
测试
EN
Research-grade reagents
H-CD19 CAR-41BB GFP+ Lentivirus (Human-Derived CAR)
Item No.:
GE20CARV-02
Specifications:
1 × 10^8 TU
Update Time：2025-07-24
Chimeric antigen receptor T cells (CAR-T cells) refer to T cells that have been genetically engineered to express an artificial T-cell receptor, thereby acquiring anti-tumor capabilities. They are called "chimeric antigen receptors" because the receptor structure simultaneously combines both antigen-binding and T-cell activation functions. CAR-T cell therapy involves several key steps: first, T cells are collected from the patient; next, the CAR construct is delivered into these T cells using a viral vector in vitro; finally, the modified T cells are expanded outside the body before being infused back into the patient. CAR-T cell therapy has already achieved global success in treating B-cell leukemia. Dongling Bio offers CAR lentiviruses targeting the human CD19 molecule, including both human- and mouse-derived CARs, which can be used for in vitro and preclinical research related to CAR-T cell therapies.
Example illustration:
Figure 1: Healthy donor-derived CD8+ T cells were infected with Dongling H-41BB-GFP CAR virus. After 72 hours of infection, flow cytometry revealed a CAR-positive T-cell rate of 63% (A). Five days post-infection, CAR-T cell-mediated cytotoxic activity against target cells (CD19+ K562) was assessed, yielding data on the killing efficiency of CAR-T cells at various T-to-target (CD19+ K562) ratios.
Figure 2: CAR-T cells and uninfected CAR control T cells were infused back into NSG mice implanted with Luciferase+RAJI leukemia cells. In vivo imaging was used to monitor the growth of leukemia cells within the mice (A), and survival curves were recorded (B).
Previous page
Contact Information
Xishan Mobile Website
Xishan Official WeChat